Results 281 to 290 of about 38,942 (318)
Some of the next articles are maybe not open access.
Retina, 2011
The purpose of this study was to compare photodynamic therapy (PDT), ranibizumab, and ranibizumab with PDT in polypoidal choroidal vasculopathy.In this retrospective comparative study, 30 eyes of 30 patients with polypoidal choroidal vasculopathy were assigned to 1 of the 3 groups. The patients in Group 1 (n = 11) received 1 session of PDT.
Amalia Ntouraki +5 more
openaire +3 more sources
The purpose of this study was to compare photodynamic therapy (PDT), ranibizumab, and ranibizumab with PDT in polypoidal choroidal vasculopathy.In this retrospective comparative study, 30 eyes of 30 patients with polypoidal choroidal vasculopathy were assigned to 1 of the 3 groups. The patients in Group 1 (n = 11) received 1 session of PDT.
Amalia Ntouraki +5 more
openaire +3 more sources
Intravitreal Ranibizumab and Bevacizumab: A Review of Risk
Seminars in Ophthalmology, 2007Ranibizumab (Lucentis), a recombinant monoclonal antibody, blocks all active forms of vascular endothelial growth factor A and was the first treatment for age-related macular degeneration shown to improve visual acuity in a substantial percentage of patients rather than slowing visual loss.
Rima M. Dafer +3 more
openaire +3 more sources
The safety of bevacizumab and ranibizumab in clinical studies
International Ophthalmology, 2015In comparing the safety of ranibizumab versus bevacizumab in age-related macular degeneration, the meta-analyses published thus far have given conflicting results, particularly about the risk of venous thrombotic events and ocular inflammation. From the comparison of the design and the findings of these meta-analysis, we tried to identify the potential
Mauro De Rosa, Andrea Messori
openaire +3 more sources
Effects of Ranibizumab on Exudative Disciform Scars
Ophthalmic Surgery, Lasers and Imaging Retina, 2009Background and Objective: To evaluate the effect of intravitreal ranibizumab in patients with leaking disciform scars. Patients and Methods: In this retrospective case series, 31 eyes received one or two ranibizumab injections for treatment of choroidal neovascularization.
Jeffrey S. Heier +11 more
openaire +3 more sources
Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment
International ophtalmology, 2022Elçin Süren +6 more
semanticscholar +1 more source
Eye
To compare the safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in treatment of Retinopathy of prematurity (ROP) METHODS: Retrospective study that included newborns with type 1 ROP who received intravitreal Bevacizumab (Avastin) or Ranibizumab (Accentrix) or Ranibizumab biosimilar (Razumab).
Puja Maitra +6 more
openaire +2 more sources
To compare the safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in treatment of Retinopathy of prematurity (ROP) METHODS: Retrospective study that included newborns with type 1 ROP who received intravitreal Bevacizumab (Avastin) or Ranibizumab (Accentrix) or Ranibizumab biosimilar (Razumab).
Puja Maitra +6 more
openaire +2 more sources
Ranibizumab for retinal angiomatous proliferation
Graefe's Archive for Clinical and Experimental Ophthalmology, 2009Dear Editor, We read with great interest the article by Konstantinidis et al. [1] on the efficacy of intravitreal ranibizumab in patients with retinal angiomatous proliferation (RAP). They reported favorable results in a series of 31 patients, with statistically significant improvement of the visual acuity by a mean of 2.7 lines after receiving five ...
Rouvas, Alexandros A. +2 more
openaire +2 more sources
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?
Eye, 2022Ashish Sharma +5 more
semanticscholar +1 more source
Cerebrovascular Accidents in Ranibizumab
Ophthalmology, 2009Takuhiro Yamaguchi +3 more
openaire +3 more sources